Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

Cyclophosphamide 3167Cisplatin 3163Carboplatin 2940Paclitaxel 2675Radiotherapy 2648Gemcitabine 2548pembrolizumab 2334Docetaxel 2158Bevacizumab 2129Fluorouracil 1822Capecitabine 1785Oxaliplatin 1713Dexamethasone 1591Nivolumab 1517Doxorubicin 1479Rituximab 1455Etoposide 1342Magnetic Resonance Spectroscopy 1270Irinotecan 1235Leucovorin 1217Cytarabine 1124Pemetrexed 1064Drug Therapy 1062fludarabine 1052Vincristine 958Specimen Handling 940Prednisone 927Cetuximab 921Lenalidomide 917Trastuzumab 903

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × apraclonidine × Clear all
NCT05045248 2021-09-16

Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis

American University of Beirut Medical Center

Phase 2 Completed
10 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡